{"id":"W3204946916","doi":"10.1016/j.annonc.2021.08.1047","title":"525P Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Genentech; Astellas Pharma; Eisai; MacroGenics; Moderna; Innovent Biologics; Sierra Oncology; Incyte; Ipsen; BeiGene; Tizona Therapeutics; Puma Biotechnology; Revolution Medicines; Regeneron Pharmaceuticals; Alexion Pharmaceuticals; Amgen; Pfizer; EMD Serono; Mersana Therapeutics; Symphogen; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Cancer research; Pharmacodynamics; Transcription factor; Pharmacology; Pharmacokinetics; Biology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004509032,0.0003872007,0.0006328428,0.0001781887,0.0001445368,0.0003583519,0.0001789824,0.0003634329,0.001723734],"category_scores_gemma":[0.0005734669,0.0001596713,0.0004439225,0.0002326651,0.0003231301,0.0002425141,0.0001246404,0.001209827,0.000331063],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003811373,"about_ca_system_score_gemma":0.0003247044,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006656687,"about_ca_topic_score_gemma":0.001167774,"domain_scores_codex":[0.9998554,0.00005517445,0.00001022723,0.00002166248,0.00002768975,0.00002985601],"domain_scores_gemma":[0.9997116,0.0001103422,0.00005687618,0.00002511224,0.00001775619,0.0000783643],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2714166,0.01244219,0.0174366,0.0006683246,0.001092146,0.00063682,0.0003141039,0.01214541,0.3820968,0.0005159816,0.00422539,0.2970096],"study_design_scores_gemma":[0.06780636,0.6424615,0.1512556,0.00007852256,0.001669355,0.002260603,0.0001671065,0.007377523,0.1126627,0.0005750984,0.01359617,0.00008940072],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957262,0.001298598,0.000472296,0.0001777181,0.00002227548,0.0001164359,0.0006149626,0.00003828563,0.001533179],"genre_scores_gemma":[0.9962929,0.0007131406,0.0002965399,0.0001414492,0.00002565117,0.00007459596,0.001358102,0.00001212057,0.001085423],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001723734,"threshold_uncertainty_score":0.005766451,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04660825120478091,"score_gpt":0.3696147963894496,"score_spread":0.3230065451846687,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}